Intrinsic Value of S&P & Nasdaq Contact Us

Accolade, Inc. ACCD NASDAQ

NASDAQ Global Select • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
40/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.03
+0.1%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Accolade, Inc. (ACCD) , forward earnings yield 5.13%.

Criteria proven by this page:

  • VALUE (50/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
  • Forward P/E 19.5
  • Analyst consensus target $7.03 (+0.1% upside) — modest upside expected.

Overall SharesGrow Score: 40/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score
40/100
SG Score
View full scorecard →
~
VALUE
50/100
Price-to-Earnings & upside
Proven by this page
FUTURE
34/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
53/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — ACCD

Valuation Multiples
P/E (TTM)0.0
Forward P/E19.5
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.27
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.33
Forward EPS (Est.)$0.36
Book Value / Share$0.00
Revenue / Share$5.53
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield5.13%
Dividend Yield0.00%
Analyst Target$7.03 (+0.1%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2018 $-1.77 $76.83M $-61.29M -79.8%
2019 $-1.63 $94.81M $-56.5M -59.6%
2020 $-1.05 $132.51M $-51.37M -38.8%
2021 $-1.72 $170.36M $-50.65M -29.7%
2022 $-1.93 $310.02M $-123.12M -39.7%
2023 $-6.45 $363.14M $-459.65M -126.6%
2024 $-1.33 $414.29M $-99.81M -24.1%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message